ArticleAnnals of surgical oncology2026
Well-Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Author Reflections: Retroperitoneal and Extremity Liposarcoma: An Opportunity to Harmonize Heterogeneity.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetroperitoneal (RP) liposarcoma (LPS) is characterized by histologic subtype and grade. This study sought to define outcomes for a novel subset of well-differentiated (WD) RP LPS defined by anatomic location in the psoas muscle.
methodsData were reviewed for all patients with primary WD LPS who underwent curative-intent complete resection at our sarcoma referral center from March 2006 to September 2021. For the study patients, clinicopathologic data were summarized. Crude cumulative incidences of local recurrence (LR) and disease-specific death (DSD) were estimated.
resultsThe 254 patients who met the inclusion criteria were stratified by location of their tumor: 12 RP psoas patients (group A), 123 RP non-psoas patients (group B), and 119 extremity patients (group C). Tumor size was greater in groups A (median, 20.0 cm) and B (median, 25.0 cm) versus group C (median, 15.0 cm; standardized mean difference [SMD], 0.747). Four patients (33 %) in group A underwent concomitant resection of muscle or nerve. In group B, 120 patients (97.5 %) had at least one organ resected (SMD, 5.606). During a median follow-up period of 8.8 years, no LR occurred in group A. The 5-year incidence of LR was 16.3 % in group B and 2.9 % in group C (p < 0.001). No DSDs occurred in group A or C, whereas the 5-year incidence of DSD was 1.9 % in group B.
conclusionsIn psoas WD LPS, local control rates and survival are highly favorable after surgery and approximate those seen for patients with extremity disease. With further multicenter validation, a more conservative approach to management may be indicated for this anatomically defined subset of RP liposarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.